DE69233108D1 - Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g - Google Patents

Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g

Info

Publication number
DE69233108D1
DE69233108D1 DE69233108T DE69233108T DE69233108D1 DE 69233108 D1 DE69233108 D1 DE 69233108D1 DE 69233108 T DE69233108 T DE 69233108T DE 69233108 T DE69233108 T DE 69233108T DE 69233108 D1 DE69233108 D1 DE 69233108D1
Authority
DE
Germany
Prior art keywords
human
proteins
inhibitors
neutrophile elastase
cathepsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233108T
Other languages
English (en)
Other versions
DE69233108T2 (de
Inventor
Charles Ley
Charles Ladner
Kosow Guterman
Lindsay Roberts
William Markland
Baribault Kent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/664,989 external-priority patent/US5223409A/en
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of DE69233108D1 publication Critical patent/DE69233108D1/de
Application granted granted Critical
Publication of DE69233108T2 publication Critical patent/DE69233108T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69233108T 1991-03-01 1992-02-28 Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g Expired - Lifetime DE69233108T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US664989 1991-03-01
US07/664,989 US5223409A (en) 1988-09-02 1991-03-01 Directed evolution of novel binding proteins
US71583491A 1991-06-17 1991-06-17
US715834 1991-06-17
PCT/US1992/001501 WO1992015605A2 (en) 1991-03-01 1992-02-28 Inhibitors of human neutrophil elastase and human cathepsin g

Publications (2)

Publication Number Publication Date
DE69233108D1 true DE69233108D1 (de) 2003-07-31
DE69233108T2 DE69233108T2 (de) 2004-04-29

Family

ID=27099103

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69233108T Expired - Lifetime DE69233108T2 (de) 1991-03-01 1992-02-28 Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
DE69233760T Expired - Fee Related DE69233760D1 (de) 1991-03-01 1992-02-28 Inhibitoren der menschlichen Elastase von Neutrophilen
DE0573603T Pending DE573603T1 (de) 1991-03-01 1992-02-28 Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69233760T Expired - Fee Related DE69233760D1 (de) 1991-03-01 1992-02-28 Inhibitoren der menschlichen Elastase von Neutrophilen
DE0573603T Pending DE573603T1 (de) 1991-03-01 1992-02-28 Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g.

Country Status (9)

Country Link
EP (2) EP0573603B1 (de)
JP (1) JP3819931B2 (de)
AT (2) ATE431364T1 (de)
AU (1) AU1581692A (de)
CA (1) CA2105304C (de)
DE (3) DE69233108T2 (de)
DK (1) DK0573603T3 (de)
ES (1) ES2124203T3 (de)
WO (1) WO1992015605A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
US5714470A (en) * 1991-08-22 1998-02-03 Merrell Pharmaceuticals, Inc. Orally-active elastase inhibitors
US5478811A (en) * 1991-08-22 1995-12-26 Merrell Dow Pharmaceuticals Inc. Orally-active elastase inhibitors
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
PT762887E (pt) * 1994-06-02 2002-01-30 Merrell Pharma Inc Derivados do enol acetilado como pro-farmacos de inibidores de elastase
NZ284766A (en) * 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
EP0699750A1 (de) * 1994-06-07 1996-03-06 Gesellschaft für biotechnologische Forschung mbH (GBF) Eine Sammling an Phagemiden, eine Sammling von Escherichia coli Zellen die diese Phagemide tragen, eine Sammling an Phagemid-Partikeln die daraus hergestellt würden und Phagemid-Partikel die durch dieses Verfahren erhalten würden
WO1996009411A1 (en) * 1994-09-21 1996-03-28 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5948886A (en) * 1996-11-20 1999-09-07 Hoechst Marion Roussel, Inc. Acylated enol derivatives of α-ketoesters and α-ketoamides
US6172044B1 (en) 1995-12-01 2001-01-09 Aventis Pharmaceuticals Inc. Acylated enol derivative of α-ketoesters and α-ketoamides
HU226419B1 (en) 1996-03-11 2008-12-29 Aerovance Human bikunin
DK1374891T3 (da) * 1998-12-22 2009-01-26 Bayer Ag Fremgangsmåde til fremskyndelse af hastigheden af mucociliær clearance
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
EP1201249A1 (de) * 2000-10-31 2002-05-02 Debiopharm S.A. Suspension von EPI-HNE-4, daraus hergestelltes Trockenpulveraerosol, Herstellungsverfahren und Arzneimittel enthaltend diese Suspension- oder Aerosolzubereitung und ihre Verwendung
AU2002217014B2 (en) * 2000-10-31 2006-11-02 Debiopharm S.A. Suspension of an EPI-hNE protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2006017355A2 (en) * 2004-07-13 2006-02-16 Bayer Pharmaceuticals Corporation Improved aprotinin variants
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
MX2011006483A (es) 2008-12-16 2011-07-13 Novartis Ag Sistemas de despliegue en levadura.
CN110055221B (zh) * 2019-04-16 2021-10-08 清华大学 一种基于细胞三维打印技术的类脑疾病治疗组织模型及其制备方法与应用
US20220354833A1 (en) 2019-09-17 2022-11-10 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
EP4252850A3 (de) 2020-04-16 2023-11-15 Mereo Biopharma 4 Limited Methoden beinhaltend neutrophile elastase inhibitor alvelestat zur behandlung von atemwegserkrankung aufgrund von alpha-1 antitrypsin mangel
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
AU600226B2 (en) * 1985-02-04 1990-08-09 Merrell Pharmaceuticals Inc. Novel peptidase inhibitors
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
IL91501A (en) * 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
ATE114332T1 (de) * 1989-05-13 1994-12-15 Bayer Ag Proteinaseninhibitoren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel.

Also Published As

Publication number Publication date
JPH06510522A (ja) 1994-11-24
EP0573603B1 (de) 2003-06-25
ES2124203T1 (es) 1999-02-01
AU1581692A (en) 1992-10-06
EP0573603A1 (de) 1993-12-15
EP1325931A1 (de) 2003-07-09
DK0573603T3 (da) 2003-10-20
CA2105304C (en) 2005-10-04
WO1992015605A2 (en) 1992-09-17
EP1325931B1 (de) 2009-05-13
CA2105304A1 (en) 1992-09-02
ATE431364T1 (de) 2009-05-15
ATE243710T1 (de) 2003-07-15
WO1992015605A3 (en) 1992-12-23
DE69233108T2 (de) 2004-04-29
DE573603T1 (de) 1999-05-06
ES2124203T3 (es) 2004-04-16
JP3819931B2 (ja) 2006-09-13
DE69233760D1 (de) 2009-06-25

Similar Documents

Publication Publication Date Title
DE69233108D1 (de) Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
DE19975040I2 (de) Medikamente enthaltend Salmeterol und Fluticason
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
DK0416950T3 (da) Medikamenter
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
NO975192D0 (no) Bicykliske aromatiske forbindelser
DE69704619D1 (de) Bisaromatische verbindungen, sie enthaltende pharmazeutische und kosmetische zusammensetzungen und verwendungen
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
PT92995A (pt) Metodo para o tratamento da disfuncao leucocita com gm-csf
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
EP0373771A3 (de) Neue pharmazeutische Anwendungen von Cystatinen
DE69314586T2 (de) Arzneimittelzusammensetzung enthaltend TCF-II
BR0114339A (pt) Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina
DE69201975D1 (de) Pyrimido-benzothiazinderivate zur Behandlung von Entzündung, Allergie and kardiovaskulären Erkrankung.
UA9703A (uk) Антипротеіназний засіб
RU93052444A (ru) Лекарственный препарат бан
UA37445A (uk) Протизапальний засіб
ITMI910114V0 (it) Struttura di calza ortopedica in particolare per la cura e la prevenzione del valgismo dell'alluce
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
YU36499A (sh) Primena 1-/4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropirid -1-il/2-(6,7-dimetoksinaft-2-il)etana za dobijanje medikamenata za neurotrofno dejstvo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition